03-Sep-2015 - Forbion Capital Partners

Bristol-Myers Squibb enters agreement to acquire Promedior, Inc.

Providing exclusive right to novel PRM-151 in development for fibrotic diseases

Bristol-Myers Squibb Company and Promedior, Inc. announced that the companies have entered into an agreement that grants Bristol-Myers Squibb an exclusive right to acquire Promedior and gain worldwide rights to its lead asset PRM-151, a recombinant form of human pentraxin-2 protein in Phase 2 development for the treatment of idiopathic pulmonary fibrosis (IPF) and myelofibrosis (MF). PRM-151 has been granted Fast Track designation in the U.S. and Orphan designation in the U.S. and Europe for the treatment of MF and Orphan Designation in the U.S. and Europe for the treatment of IPF. Total aggregate payments to Promedior under the agreement have the potential to reach $1.25 billion, which includes an upfront cash payment for the right to acquire Promedior, an exercise fee payable if Bristol-Myers Squibb elects to exercise its right to acquire the company, and subsequent clinical and regulatory milestone payments.

PRM-151 has been shown in multiple preclinical models to regulate monocytes and macrophages at areas of tissue damage to prevent and reverse fibrosis, including IPF, acute and chronic nephropathy, liver fibrosis, and age-related macular degeneration. Promedior has advanced PRM-151 into clinical trials focused on two orphan fibrotic diseases (MF and IPF). It is anticipated that the Phase 2 trials in MF and IPF will be initiated in the coming weeks. Bristol-Myers Squibb can exercise its right to acquire Promedior upon completion of either of these trials.

Facts, background information, dossiers
  • Bristol-Myers Squibb
  • Promedior
  • acquisitions
More about Forbion Capital Partners
  • News

    Forbion Closes Oversubscribed Fourth Life Sciences VC Fund at EUR 360 million

    Forbion has announced the final close of its new flagship fund, Forbion IV. The oversubscribed fund closed at EUR 360 million in capital commitments, significantly above its original target of EUR 250 million. Forbion IV, like its predecessor fund, Forbion III, will primarily focus on oppo ... more

    Closing of public offering of Argos Therapeutics

    Forbion Capital Partners announces that its portfolio company Argos Therapeutics has closed its initial public offering. The initial public offering price was $8.00 per ordinary share. Argos' ordinary shares have listed on the NASDAQ Global Market and began trading under the symbol "ARGS" o ... more

More about Bristol-Myers Squibb